Iloperidone (Fanapt®): Fan or not?

2011 ◽  
Vol 1 (6) ◽  
pp. 137-139
Author(s):  
Uma Newton ◽  
Tiffany-Jade Kreys
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Mechanism Of Action ◽  
Food And Drug Administration ◽  
New Drug ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence

Iloperidone was approved by the Food and Drug Administration (FDA) in May of 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

New Drug Review-Ezogabine (Potiga): Seizing the seizure

2011 ◽  
Vol 1 (6) ◽  
pp. 135-136
Author(s):  
Misty L. Gonzalez
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Mechanism Of Action ◽  
New Drug ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence ◽  
Drug Review

Ezogabine was approved by the Food and Drug Administration (FDA) in June of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Saphris: Does a unique delivery system equal a unique drug?

2011 ◽  
Vol 1 (6) ◽  
pp. 133-134
Author(s):  
Kelly N. Gable
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Delivery System ◽  
Mechanism Of Action ◽  
Food And Drug Administration ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence

Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

scholarly journals Viibryd (Vilazodone): Viable option or for the byrds?

2011 ◽  
Vol 1 (6) ◽  
pp. 140-141
Author(s):  
Misty L. Gonzalez
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Mechanism Of Action ◽  
Food And Drug Administration ◽  
Viable Option ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence

Vilazodone was approved by the Food and Drug Administration (FDA) in January of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

New Drug Review: Clobazam (Onfi®) - A “new” anticonvulsant option

2011 ◽  
Vol 1 (6) ◽  
pp. 126-127
Author(s):  
Jamie Holmes ◽  
Robin Hieber
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Mechanism Of Action ◽  
New Drug ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence ◽  
Drug Review

Clobazam was approved by the Food and Drug Administration (FDA) in October of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

New Drug Review: Lurasidone (Latuda®) - The new antipsychotic on the block

2011 ◽  
Vol 1 (6) ◽  
pp. 131-132 ◽  
Author(s):  
Kelly N. Gable
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Mechanism Of Action ◽  
New Drug ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence ◽  
Drug Review

Lurasidone was approved by the Food and Drug Administration (FDA) in 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

New Drug Review: Gabapentin enacarbil extended release (Horizant™) – A new formulation on the horizon

2011 ◽  
Vol 1 (6) ◽  
pp. 128-130
Author(s):  
Amy B. Werremeyer
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Extended Release ◽  
Gabapentin Enacarbil ◽  
New Drug ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
New Formulation ◽  
Trial Evidence ◽  
Drug Review

Gabapentin enacarbil was approved by the Food and Drug Administration (FDA) in April of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

scholarly journals Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

2020 ◽  
Vol 3 (11) ◽  
pp. e2024406
Author(s):  
Aviv Ladanie ◽  
Andreas M. Schmitt ◽  
Benjamin Speich ◽  
Florian Naudet ◽  
Arnav Agarwal ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Cancer Therapies ◽  
Clinical Trial Evidence ◽  
Trial Evidence

scholarly journals 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

2021 ◽  
Vol 14 (2) ◽  
pp. 145
Author(s):  
Othman Al Musaimi ◽  
Danah Al Shaer ◽  
Fernando Albericio ◽  
Beatriz de la Torre
Keyword(s):  
Adverse Effects ◽  
Global Health ◽  
Drug Administration ◽  
Mode Of Action ◽  
Chemical Structure ◽  
Food And Drug Administration ◽  
Health Crisis ◽  
New Drug ◽  
Target Mode ◽  
The Us

2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.

Sign in / Sign up

Export Citation Format

Share Document